HC Wainwright Has Negative Forecast for Ardelyx Q1 Earnings

Ardelyx, Inc. (NASDAQ:ARDX) – Stock analysts at HC Wainwright decreased their Q1 2025 earnings per share (EPS) estimates for shares of Ardelyx in a note issued to investors on Monday, November 11th. HC Wainwright analyst E. Arce now forecasts that the biopharmaceutical company will earn ($0.15) per share for the quarter, down from their previous forecast of ($0.05). HC Wainwright currently has a “Neutral” rating and a $5.50 target price on the stock. The consensus estimate for Ardelyx’s current full-year earnings is ($0.18) per share. HC Wainwright also issued estimates for Ardelyx’s Q2 2025 earnings at ($0.12) EPS, Q3 2025 earnings at ($0.10) EPS, Q4 2025 earnings at ($0.09) EPS, FY2025 earnings at ($0.47) EPS, FY2026 earnings at $0.03 EPS, FY2027 earnings at $0.63 EPS and FY2028 earnings at $1.06 EPS.

A number of other equities research analysts also recently issued reports on ARDX. StockNews.com raised shares of Ardelyx from a “sell” rating to a “hold” rating in a research note on Wednesday, July 31st. Wedbush restated an “outperform” rating and set a $11.00 price target on shares of Ardelyx in a research note on Friday, August 2nd. Finally, Citigroup lowered their price target on Ardelyx from $12.00 to $10.00 and set a “buy” rating for the company in a research report on Monday, November 4th. Three investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $10.42.

Ardelyx Stock Down 2.0 %

Shares of ARDX opened at $4.50 on Wednesday. The company’s 50-day moving average price is $5.99 and its 200 day moving average price is $6.28. Ardelyx has a 12-month low of $3.82 and a 12-month high of $10.13. The company has a debt-to-equity ratio of 0.64, a quick ratio of 3.87 and a current ratio of 4.03.

Hedge Funds Weigh In On Ardelyx

Several large investors have recently bought and sold shares of ARDX. Redmile Group LLC acquired a new position in shares of Ardelyx during the 1st quarter worth about $16,020,000. Millennium Management LLC boosted its holdings in Ardelyx by 142.8% in the second quarter. Millennium Management LLC now owns 3,203,090 shares of the biopharmaceutical company’s stock valued at $23,735,000 after purchasing an additional 1,883,995 shares in the last quarter. Price T Rowe Associates Inc. MD increased its stake in Ardelyx by 68.0% in the first quarter. Price T Rowe Associates Inc. MD now owns 3,913,863 shares of the biopharmaceutical company’s stock valued at $28,572,000 after purchasing an additional 1,584,597 shares during the last quarter. Rubric Capital Management LP raised its holdings in Ardelyx by 68.5% during the third quarter. Rubric Capital Management LP now owns 3,060,191 shares of the biopharmaceutical company’s stock worth $21,085,000 after purchasing an additional 1,243,606 shares in the last quarter. Finally, Vanguard Group Inc. lifted its position in shares of Ardelyx by 2.8% during the 1st quarter. Vanguard Group Inc. now owns 13,391,855 shares of the biopharmaceutical company’s stock worth $97,761,000 after buying an additional 365,809 shares during the last quarter. Hedge funds and other institutional investors own 58.92% of the company’s stock.

Insider Transactions at Ardelyx

In related news, insider David P. Rosenbaum sold 49,564 shares of Ardelyx stock in a transaction on Friday, September 27th. The stock was sold at an average price of $6.92, for a total value of $342,982.88. Following the completion of the transaction, the insider now directly owns 301,946 shares in the company, valued at approximately $2,089,466.32. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other Ardelyx news, CEO Michael Raab sold 35,000 shares of the stock in a transaction that occurred on Wednesday, September 11th. The shares were sold at an average price of $5.61, for a total value of $196,350.00. Following the sale, the chief executive officer now directly owns 1,220,608 shares of the company’s stock, valued at approximately $6,847,610.88. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider David P. Rosenbaum sold 49,564 shares of Ardelyx stock in a transaction on Friday, September 27th. The stock was sold at an average price of $6.92, for a total transaction of $342,982.88. Following the sale, the insider now directly owns 301,946 shares of the company’s stock, valued at approximately $2,089,466.32. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 267,983 shares of company stock valued at $1,632,802. 5.90% of the stock is currently owned by company insiders.

Ardelyx Company Profile

Ardelyx, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company’s lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation.